Combination therapy resulted in a decrease in the percentage of Ki67+ glioma cells in 3 of 4 “responsive” models, G20, G26, and G30 (p < 0.0001), and in 1 of 12 “non-responsive” models, G33 (p = 0.0276), while for other models no significant changes in the percentage of Ki67+ cells were observed. Here, MKI67 is linked to central nervous system cancer.